Combining medication with sustained lifestyle changes and regular follow-up yields the best chance of meaningful, long-term weight loss. Medications help tip the energy balance by reducing appetite or increasing satiety, but they work best when paired with ongoing efforts to eat healthier, move more, and change behaviors. Regular follow-up is essential to monitor effectiveness and safety, adjust dosages, manage side effects, and support adherence and motivation. Clinicians typically reassess response after several weeks and months to ensure the plan is working and safe. So the strongest approach is using pharmacotherapy together with lifestyle modifications and ongoing follow-up.

Adolescent bariatric evaluation hinges on a coordinated, multidisciplinary approach delivered at specialized centers. Teens present unique needs: ongoing growth and development, family dynamics, psychological factors, and the long-term commitment required to sustain weight management after surgery. A true program brings together a team—pediatric obesity specialists, surgeons, dietitians, psychologists or psychiatrists, social workers, and exercise professionals—who collaborate to assess medical risk, nutritional status, mental health, behavioral readiness, and family support. Having defined BMI thresholds with metabolic or psychosocial comorbidities helps identify appropriate candidates, ensuring that potential benefits outweigh risks. Psychosocial readiness is crucial because the teen must be prepared to adhere to significant lifestyle changes, follow post-operative dietary plans, and manage lifelong supplements and follow-up care. Long-term follow-up is essential to monitor growth and development, nutritional status, weight trajectory, and psychosocial well-being, and to adapt the plan as the young person transitions into adulthood. Nutritional counseling or psychological assessment alone, while important, don’t capture the full safety and efficacy picture. The best choice reflects a comprehensive, center-based, multidisciplinary process with clear criteria and ongoing support, which is why it stands as the essential component.

In the United States, bariatric surgery trends show that sleeve gastrectomy and Roux-en-Y gastric bypass are the most commonly performed procedures, with sleeve gastrectomy increasing in use. This shift happened because sleeve gastrectomy offers effective weight loss with a simpler operation and fewer long-term issues compared to other methods, contributing to its rising popularity. Adjustable gastric banding has declined and no longer holds a leading position, while vertical banded gastroplasty is now rarely performed. Additionally, most bariatric surgeries are done laparoscopically, not via an open approach. So the statement that sleeve gastrectomy and Roux-en-Y are the most common procedures, and that sleeve is increasing, accurately reflects current practice.

The guiding idea is to create a sensible, sustainable energy deficit that also meets all essential nutrient needs, with the target tailored to the individual’s size and activity. For a 45-year-old woman with BMI 31.5, choosing a daily intake of 1200–1500 kcal adjusted for body weight provides a clear, modest deficit (roughly 500–750 kcal below maintenance for many people) while staying above dangerously low levels. This allows personalized tuning: the higher end if she has greater energy needs or is more active, the lower end if her needs are smaller, ensuring both weight loss and nutrient adequacy. Why the other options aren’t as suitable: a small deficit around 250 kcal/day would produce very slow weight loss and might stall. A fixed range like 1500–1800 kcal/day could fail to create enough deficit for weight loss in someone with higher maintenance needs, and a very low-calorie plan (<800 kcal/day) requires close medical supervision and isn’t appropriate for general guidelines.

Metformin often causes gastrointestinal side effects, with diarrhea being one of the most common and dose-limiting issues. When diarrhea is persistent or severe, it can make continuing metformin intolerable, prompting a switch to another agent such as glyburide. Other options don’t fit as well: metformin isn’t typically associated with weight gain (it’s usually weight-neutral or may cause weight loss), hypoglycemia is not a common direct result of metformin (though it can occur with other drugs that are added), and hypertension isn’t tied to metformin’s adverse effects.